查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081929

囊腫纖維化市場：按治療方法、給藥途徑、最終用戶和分銷管道分類的全球市場預測，2026-2032 年

Cystic Fibrosis Market by Treatment Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，囊腫纖維化市場規模將達到 136.1 億美元，複合年成長率為 9.79%。

主要市場統計數據
基準年 2025 70.7億美元
預計年份：2026年 77.1億美元
預測年份 2032 136.1億美元
複合年成長率 (%) 9.79%

囊腫纖維化市場簡介

囊腫纖維化是一種危及生命的體染色體隱性遺傳疾病，由CFTR基因的致病突變所引起。這會導致氯離子和碳酸氫根離子轉運受損、黏液增稠、反覆呼吸道感染疾病、胰臟功能衰竭以及多重器官併發症。囊腫纖維化市場受其沉重的臨床負擔、終身治療需求以及快速發展的治療標準所驅動，這些標準主要包括CFTR調變器、氣道清除、抗感染藥物、祛痰藥、營養支持和多學科疾病管理。

囊腫纖維化治療環境的變革性變化

囊腫纖維化的治療模式正從症狀管理轉向以基因型為基礎的緩解疾病。 CFTR調變器，尤其是對合格的患者療效顯著的三重聯合治療，改變了人們對肺功能、肺部症狀進展減緩、營養狀況和生活品質的預期。這種轉變正在重塑藥品、診斷、專科藥局、伴隨診斷和長期監測等領域的需求模式。

人工智慧（AI）的累積影響

人工智慧（AI）正日益成為囊腫纖維化整體研究和治療中一股重要的推動力量。 AI驅動的影像分析能夠量化CT和MRI掃描中的肺部結構性病變，而機器學習模型正被評估用於利用肺功能測定、症狀、微生物學檢測、穿戴式裝置資料和電子健康記錄來預測肺部急性惡化。這些工具能夠幫助臨床醫生早期識別疾病進展並制定個人化的追蹤方案。

主要區域洞察：亞太地區、北美地區、歐洲、拉丁美洲、中東和非洲

北美仍然是囊腫纖維化市場最成熟的地區，其中美國和加拿大主導。在這些國家，新生兒篩檢、認證醫療中心、病患登記系統以及先進的CFTR調變器的普及，都支撐了較高的治療滲透率。歐洲也在穩步發展，擁有強大的專家網路、國家登記系統和保險報銷機制，儘管歐盟成員國和非歐盟市場在治療普及方面存在差異。

主要區域集團分析：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

歷史上，由於囊腫纖維化在東協地區的盛行率低於歐洲人群，且診斷基礎設施存在顯著差異，該地區的囊性纖維化診斷率一直較低。然而，基因組醫學的擴展、兒童呼吸系統醫療設備的加強以及轉診網路的建立，正在改善病例的識別。在海灣合作理事會（GCC）國家，對專業醫療基礎設施、基因檢測、婚前篩檢和攜帶者篩檢計畫以及罕見疾病應對系統的投資，正在為提高早期診斷和精準治療的可及性創造更多機會。

對主要囊腫纖維化市場中各國的關鍵洞察。

美國擁有龐大的確診患者群體、先進的醫療中心基礎設施、新生兒篩檢，並在合格的患者中廣泛使用CFTR調變器，已成為全球囊腫纖維化創新領域的商業性中心。加拿大憑藉其集中評估系統、省級報銷流程和完善的專科醫療服務，展現出類似的臨床成熟度。墨西哥和巴西加強了診斷、新生兒篩檢和專科醫生服務，但成本效益和地區差異仍然影響著治療的可近性。

為行業領導者提供的實用建議

行業領導者應優先考慮廣泛的基因型覆蓋、持續的真實世界臨床結果以及符合當地保險公司期望的准入策略。 CFTR調變器、抗感染藥物、祛痰藥、基因療法或數位監測工具的研發者應儘早投資於生物標記檢驗、註冊合作、患者報告結局（PRO）以及能夠證明減少病情加重、避免住院、改善肺功能和長期生活品質的證據包。

調查方法

本調查方法基於已驗證的二手研究，包括同行評審的囊腫纖維化文獻、公共衛生指南、監管資訊、臨床試驗資料庫、新生兒篩檢參考資料、患者檢驗資訊以及來自經認證的囊腫纖維化基金會和專業組織的公開資訊。市場分析著重於與產業決策相關的、經臨床檢驗且可重複的證據。

結論

囊腫纖維化市場正進入一個新階段，其特徵是人們對精準醫療、早期診斷、長期緩解疾病和公平獲取的期望日益成長。雖然CFTR調變器已經改善了許多合格的患者的治療效果，但在罕見突變、併發症嚴重、慢性感染疾病以及診斷和報銷系統有限的地區，仍然存在著巨大的未滿足需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：囊腫纖維化市場：依治療類型分類

  • CFTR調變器療法
    • 增強劑
    • 集電極
    • 擴大機
    • 聯合治療
  • 症狀治療/支持性治療
    • 祛痰藥
    • 支氣管擴張劑
    • 抗生素
    • 抗發炎藥

第8章：囊腫纖維化市場：依給藥途徑分類

  • 吸入
  • 靜脈
  • 口服

第9章：囊腫纖維化市場：依最終用戶分類

  • 家庭醫療保健
  • 醫院
  • 專科診所

第10章：囊腫纖維化市場：依通路分類

  • 物理藥房
    • 醫院藥房
    • 零售藥房
  • 網路藥房

第11章：囊腫纖維化市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：囊腫纖維化市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：囊腫纖維化市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • Alaxia SAS
  • Anthera Pharmaceuticals, Inc.
  • Arcturus Therapeutics Holdings Inc.
  • AstraZeneca PLC
  • Beyond Air, Inc.
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici SpA
  • Corbus Pharmaceuticals Holdings, Inc.
  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • Eloxx Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd
  • Galapagos NV
  • GeneTx Biotherapeutics LLC
  • Gilead Sciences, Inc.
  • Insmed Incorporated
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Neovii Biotech GmbH
  • Novartis AG
  • Novo Nordisk A/S
  • Pharmaxis Ltd.
  • Proteostasis Therapeutics, Inc.
  • PTC Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.
  • Zambon SpA
Product Code: MRR-4316E4E89581

The Cystic Fibrosis Market is projected to grow by USD 13.61 billion at a CAGR of 9.79% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.07 billion
Estimated Year [2026] USD 7.71 billion
Forecast Year [2032] USD 13.61 billion
CAGR (%) 9.79%

Cystic Fibrosis Market Introduction

Cystic fibrosis is a life-limiting, autosomal recessive disease caused by pathogenic variants in the CFTR gene, leading to impaired chloride and bicarbonate transport, thick mucus, recurrent respiratory infections, pancreatic insufficiency, and multisystem complications. The cystic fibrosis market is shaped by a high clinical burden, lifelong treatment needs, and a rapidly evolving standard of care centered on CFTR modulators, airway clearance, anti-infectives, mucolytics, nutritional support, and multidisciplinary disease management.

Verified registry and foundation data indicate that more than 105,000 people are living with diagnosed cystic fibrosis across 90-plus countries, with the highest documented prevalence in North America and Europe. Earlier diagnosis through newborn screening, longer survival, and broader access to precision therapies are expanding the treated population, while health systems continue to address gaps in equitable access, genotype coverage, infection control, and long-term outcomes.

Transformative Shifts in the Cystic Fibrosis Landscape

The cystic fibrosis landscape has shifted from symptom management toward genotype-directed disease modification. CFTR modulators, particularly highly effective triple-combination therapy for eligible patients, have changed expectations for lung function, pulmonary exacerbation reduction, nutritional status, and quality of life. This transition is reshaping demand across pharmaceuticals, diagnostics, specialty pharmacy, companion testing, and longitudinal monitoring.

At the same time, unmet needs remain substantial for people with rare or nonresponsive CFTR variants, advanced lung disease, chronic Pseudomonas aeruginosa or Burkholderia cepacia complex infection, liver disease, cystic fibrosis-related diabetes, infertility, and treatment-related access barriers. The next competitive phase is expected to emphasize mutation-agnostic strategies, mRNA and gene editing platforms, inhaled delivery systems, antimicrobial resistance management, and real-world evidence demonstrating durable clinical value.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical enabler across cystic fibrosis research and care. AI-supported image analysis can quantify structural lung disease from CT and MRI, while machine learning models are being evaluated to anticipate pulmonary exacerbations using spirometry, symptoms, microbiology, wearable data, and electronic health records. These tools can help clinicians identify deterioration earlier and personalize follow-up intensity.

AI is also accelerating drug discovery by supporting CFTR variant interpretation, protein-structure modeling, candidate screening, clinical trial enrichment, and pharmacovigilance. The cumulative impact is strongest when AI is paired with validated registries, standardized endpoints, and privacy-preserving data governance. Industry leaders should view AI as a decision-support layer rather than a replacement for specialist-led cystic fibrosis care.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

North America remains the most mature cystic fibrosis market, led by the United States and Canada, where newborn screening, accredited care centers, registries, and access to advanced CFTR modulators support high treatment penetration. Europe is similarly advanced, with strong specialist networks, national registries, and reimbursement pathways, although country-level access timelines differ across the European Union and non-EU markets.

Asia-Pacific is expanding through improved diagnosis, rising specialty-care capacity, and increasing awareness in China, India, Japan, South Korea, and Australia, but underdiagnosis and genotype diversity remain important constraints. Latin America, the Middle East, and Africa show growing clinical recognition and newborn screening adoption in select countries, yet access to modulators, sweat testing, genetic testing, and infection-control infrastructure remains uneven. These regional differences make market access, affordability, local evidence generation, and clinician training essential for sustainable growth.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

Within ASEAN, cystic fibrosis is historically underdiagnosed because the disease is less common than in populations of European ancestry and diagnostic infrastructure varies widely; however, expanding genomic medicine, pediatric pulmonology capacity, and referral networks are improving case identification. GCC countries are investing in specialized healthcare infrastructure, genetic testing, premarital and carrier screening programs, and rare disease pathways, creating opportunities for earlier diagnosis and precision treatment access.

The European Union benefits from coordinated rare disease policy, cross-border research networks, newborn screening expansion, and established cystic fibrosis registries, while BRICS markets present a mixed profile: China, India, and Brazil offer large population bases and improving specialty access, whereas affordability and diagnostic coverage remain key barriers. G7 markets lead in innovation, reimbursement sophistication, clinical trial infrastructure, and real-world evidence generation. NATO member countries overlap heavily with North American and European advanced-care markets, supporting strong clinical trial capacity, standardized treatment protocols, and high adoption of specialist-led care models.

Key Country Insights Across Major Cystic Fibrosis Markets

The United States is the global commercial anchor for cystic fibrosis innovation, supported by a large diagnosed population, advanced care-center infrastructure, newborn screening, and broad use of CFTR modulators among eligible patients. Canada shows similar clinical sophistication with centralized assessment, provincial reimbursement processes, and strong specialist care. Mexico and Brazil are strengthening diagnosis, newborn screening, and specialist access, but affordability and regional disparities continue to influence treatment uptake.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain robust cystic fibrosis care models, registries, newborn screening programs, and reimbursement systems, while Russia faces more variable access across regions. China and India are increasingly important due to expanding genetic testing, pediatric respiratory care, and rising rare disease awareness, though underdiagnosis remains significant. Japan, Australia, and South Korea combine high-quality healthcare systems with growing precision medicine adoption, supporting opportunities in diagnostics, specialty therapeutics, adherence support, and long-term outcome monitoring.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize broad genotype coverage, durable real-world outcomes, and access strategies that reflect local payer expectations. Developers of CFTR modulators, anti-infectives, mucolytics, gene-based therapies, or digital monitoring tools should invest early in biomarker validation, registry partnerships, patient-reported outcomes, and evidence packages that demonstrate reduced exacerbations, hospitalization avoidance, improved lung function, and better long-term quality of life.

Commercial and medical teams should also strengthen collaborations with cystic fibrosis centers, patient organizations, diagnostic laboratories, and public health agencies. Practical priorities include expanding newborn screening, improving sweat chloride and genetic testing access, supporting antimicrobial stewardship, reducing treatment burden, improving adherence support, and designing equitable access models for low- and middle-income markets.

Research Methodology

Research methodology is built from verified secondary research, including peer-reviewed cystic fibrosis literature, public health guidance, regulatory information, clinical trial databases, newborn screening references, patient registry insights, and publicly available information from recognized cystic fibrosis foundations and specialist organizations. Market interpretation emphasizes evidence that is clinically validated, reproducible, and relevant to industry decision-making.

The methodology combines disease epidemiology review, therapy landscape assessment, regional access evaluation, and qualitative analysis of innovation trends. Insights are triangulated across clinical standards, regulatory approvals, reimbursement patterns, registry findings, and real-world care infrastructure to provide an objective view of the cystic fibrosis market without relying on unsupported assumptions, market estimation, or forecasting.

Conclusion

The cystic fibrosis market is entering a new phase defined by precision medicine, earlier diagnosis, long-term disease modification, and rising expectations for equitable access. CFTR modulators have transformed outcomes for many eligible patients, but significant unmet needs persist for rare variants, advanced complications, chronic infection, and regions with limited diagnostic or reimbursement capacity.

Future leadership will depend on therapies and services that expand eligibility, reduce treatment burden, and prove durable value in real-world settings. Organizations that combine scientific innovation with strong access planning, registry-based evidence, and patient-centered care models will be best positioned in the global cystic fibrosis ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cystic Fibrosis Market, by Treatment Type

  • 7.1. CFTR Modulator Therapies
    • 7.1.1. Potentiators
    • 7.1.2. Correctors
    • 7.1.3. Amplifiers
    • 7.1.4. Combination Therapies
  • 7.2. Symptomatic / Supportive Therapies
    • 7.2.1. Mucolytics
    • 7.2.2. Bronchodilators
    • 7.2.3. Antibiotics
    • 7.2.4. Anti-Inflammatory Drugs

8. Cystic Fibrosis Market, by Route Of Administration

  • 8.1. Inhalation
  • 8.2. Intravenous
  • 8.3. Oral

9. Cystic Fibrosis Market, by End User

  • 9.1. Home Healthcare
  • 9.2. Hospitals
  • 9.3. Specialty Clinics

10. Cystic Fibrosis Market, by Distribution Channel

  • 10.1. Offline Pharmacy
    • 10.1.1. Hospital Pharmacy
    • 10.1.2. Retail Pharmacy
  • 10.2. Online Pharmacy

11. Cystic Fibrosis Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Cystic Fibrosis Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Cystic Fibrosis Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Abbott Laboratories
  • 15.2. AbbVie Inc.
  • 15.3. Alaxia SAS
  • 15.4. Anthera Pharmaceuticals, Inc.
  • 15.5. Arcturus Therapeutics Holdings Inc.
  • 15.6. AstraZeneca PLC
  • 15.7. Beyond Air, Inc.
  • 15.8. Boehringer Ingelheim International GmbH
  • 15.9. Chiesi Farmaceutici S.p.A.
  • 15.10. Corbus Pharmaceuticals Holdings, Inc.
  • 15.11. CRISPR Therapeutics AG
  • 15.12. Editas Medicine, Inc.
  • 15.13. Eloxx Pharmaceuticals, Inc.
  • 15.14. F. Hoffmann-La Roche Ltd
  • 15.15. Galapagos NV
  • 15.16. GeneTx Biotherapeutics LLC
  • 15.17. Gilead Sciences, Inc.
  • 15.18. Insmed Incorporated
  • 15.19. Johnson & Johnson Services, Inc.
  • 15.20. Merck & Co., Inc.
  • 15.21. Neovii Biotech GmbH
  • 15.22. Novartis AG
  • 15.23. Novo Nordisk A/S
  • 15.24. Pharmaxis Ltd.
  • 15.25. Proteostasis Therapeutics, Inc.
  • 15.26. PTC Therapeutics, Inc.
  • 15.27. Teva Pharmaceutical Industries Ltd.
  • 15.28. Vertex Pharmaceuticals Incorporated
  • 15.29. Viatris Inc.
  • 15.30. Zambon S.p.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CYSTIC FIBROSIS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CYSTIC FIBROSIS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CYSTIC FIBROSIS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CYSTIC FIBROSIS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CYSTIC FIBROSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CYSTIC FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CFTR MODULATOR THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CFTR MODULATOR THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CFTR MODULATOR THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POTENTIATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POTENTIATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POTENTIATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CORRECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CORRECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CORRECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AMPLIFIERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AMPLIFIERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AMPLIFIERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SYMPTOMATIC / SUPPORTIVE THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SYMPTOMATIC / SUPPORTIVE THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SYMPTOMATIC / SUPPORTIVE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MUCOLYTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MUCOLYTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MUCOLYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRONCHODILATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRONCHODILATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INHALATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 124. GCC CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. GCC CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. GCC CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 127. GCC CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 128. GCC CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. GCC CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. GCC CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GCC CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 148. G7 CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. G7 CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 151. G7 CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 152. G7 CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. G7 CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. G7 CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. G7 CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. NATO CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 159. NATO CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 160. NATO CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. NATO CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. NATO CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. NATO CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 173. CANADA CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. CANADA CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. CANADA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 176. CANADA CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 177. CANADA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. CANADA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. CANADA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. CANADA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 181. MEXICO CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 184. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 185. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 189. BRAZIL CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 192. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 193. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 205. GERMANY CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 208. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 209. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 213. FRANCE CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 216. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 217. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 221. RUSSIA CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. RUSSIA CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. RUSSIA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 224. RUSSIA CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 225. RUSSIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. RUSSIA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. RUSSIA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. RUSSIA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 229. ITALY CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. ITALY CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. ITALY CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 232. ITALY CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 233. ITALY CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. ITALY CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. ITALY CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. ITALY CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 237. SPAIN CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. SPAIN CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. SPAIN CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 240. SPAIN CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 241. SPAIN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. SPAIN CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. SPAIN CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. SPAIN CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 253. INDIA CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. INDIA CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. INDIA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 256. INDIA CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 257. INDIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 258. INDIA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. INDIA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. INDIA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 261. JAPAN CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 264. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 265. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 266. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 268. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 269. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 270. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 272. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 273. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 277. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 280. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 281. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 282. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)